A multicenter, open‐label, single‐arm trial of the long‐term safety of empagliflozin treatment for refractory diabetes mellitus with insulin resistance (EMPIRE‐02)
Article in Journal of Diabetes Investigation (May 2024)
The most recent citing publications are shown below. View all 335 publications that cite this research output on Dimensions.
Article in Journal of Diabetes Investigation (May 2024)
Article in Frontiers in Endocrinology (April 2024)
Preprint in Research Square (April 2024)